Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

Galapagos NV (NASDAQ:GLPG – Get Free Report) has received an average recommendation of “Reduce” from the eight research firms ...

Belgium-based biotech company Galapagos NV's (GLPG) U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a spin-off into two ...

Fintel reports that on January 23, 2025, Barclays downgraded their outlook for Galapagos NV - Depositary Receipt () (NasdaqGS:GLPG) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 48 ...

Belgian biotech company Galapagos NV plans to spin off part of its operations, creating a new listed firm with approximately €2.45 billion ($2.5 billion) in cash. The newly formed company ...

Galapagos NV is abandoning its small molecule roots to focus on cell therapy and at the same time splitting in two, with the spinout company, dedicated to acquiring a portfolio of assets, taking the ...

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667 ...

Will further expand Galapagos’ manufacturing network in the U.S. for improved patient experience.

FMR LLC controls investment funds Fidelity Management & Resear Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ ...

Barclays downgraded Galapagos (GLPG) to Underweight from Equal Weight with a price target of EUR 22, down from EUR 30. With Galapagos’ ongoing ...

A diver's journey to the Galapagos Islands aboard a small expedition ship. Diving with sharks, turtles, sea lions, rays and ...